Immunohistochemical determination of HER-2/neu, c-Kit (CD117), and vascular endothelial growth factor (VEGF) overexpression in malignant melanoma
Immunohistochemical determination of HER-2/neu, c-Kit (CD117), and vascular endothelial growth factor (VEGF) overexpression in malignant melanoma
复制标题
DOI：
10.1007/s00432-003-0509-8
复制
发表时间：
2004-02-01
影响因子：
3.6
通讯作者：
Kargas, S
中科院分区：
文献类型：
--
作者：
Potti, A;Moazzam, N;Kargas, S
目的.为了确定恶性黑色素瘤的患病率和评估分子靶点的可能预后价值，我们研究了HER-2/neu、c-Kit和血管内皮生长因子（VEGF）在该患者人群中的过表达。材料和方法。HER-2/neu，c-Kit和VEGF的过表达进行了评估，使用免疫组化检测202档案组织标本。结果只有2例（0.9%）患者显示HER-2/neu过表达，而46例（22.8%）显示c-Kit，42例（20.8%）标本显示VEGF过表达。进行的多变量分析未显示c-Kit阳性和c-Kit阴性组（P=0.36）与VEGF阳性和VEGF阴性组（P=0.25）之间的生存率存在显著差异。有趣的是，c-Kit更可能在浅表扩散型中过表达，VEGF优先在无色素性黑素瘤型中过表达。结论. HER-2/neu在黑素生成中没有作用。c-Kit（在浅表扩散性疾病中表达）和VEGF（在无色素性黑色素瘤中表达）作为分子靶点可能具有重要的治疗意义，这需要进一步研究。
Purpose. To determine the prevalence and evaluate the possible prognostic value of the molecular targets in malignant melanoma, we studied the overexpression of HER-2/neu, c-Kit, and vascular endothelial growth factor (VEGF) in this patient population. Materials and methods. Overexpression of HER-2/neu, c-Kit, and VEGF was evaluated using immunohistochemical assays in 202 archival tissue specimens. Results. Only two patients (0.9%) revealed HER-2/neu overexpression, whereas 46 (22.8%) revealed c-Kit and 42 (20.8%) specimens showed VEGF overexpression. Multivariate analysis performed did not show a significant difference in survival between c-Kit-positive and c-Kit-negative groups (P=0.36) and VEGF-positive and VEGF-negative groups (P=0.25). Interestingly, c-Kit was more likely to be overexpressed in the superficial spreading type and VEGF was overexpressed preferentially in the amelanotic melanoma type. Conclusions. HER-2/neu has no role in melanogenesis. Both c-Kit (expressed in superficial spreading disease) and VEGF (expressed in amelanotic melanoma) may have significant therapeutic implications as molecular targets, which warrants further investigation.